Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications

John Turchi, Steve M. Patrick

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

This chapter discusses the nucleotide excision repair pathway (NER) for therapeutic applications. The NER pathway involves a complex series of reactions and interactions that lead to the effective removal of damage from DNA and is crucial in maintaining genome integrity and stability. The role of NER in removing cisplatin chemotherapy-induced DNA damage and the demonstrated mechanism of resistance in multiple cancers involving increased repair presents the opportunity for intervention. Realization of this potential to sensitize cancers to cisplatin and reverse resistance of those cancers that develop insensitivity to this agent will require the development of specific agents capable of targeting the NER pathway. The possibility exists that the success of platinum therapy in the treatment of testicular cancer can be replicated in lung and ovarian cancers where the lack of response to platinum therapy is a major determinant of the dismal survival statistics associated with those diseases. Such a finding would be a watershed event that could dramatically alter treatments of human cancer.

Original languageEnglish
Title of host publicationDNA Repair in Cancer Therapy
PublisherElsevier Inc.
Pages109-117
Number of pages9
ISBN (Print)9780123849991
DOIs
StatePublished - 2012

Fingerprint

DNA Repair
Platinum
Cisplatin
DNA Damage
Neoplasms
Therapeutics
Genomic Instability
Testicular Neoplasms
Ovarian Neoplasms
Lung Neoplasms
Drug Therapy
Survival

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications. / Turchi, John; Patrick, Steve M.

DNA Repair in Cancer Therapy. Elsevier Inc., 2012. p. 109-117.

Research output: Chapter in Book/Report/Conference proceedingChapter

Turchi, John ; Patrick, Steve M. / Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications. DNA Repair in Cancer Therapy. Elsevier Inc., 2012. pp. 109-117
@inbook{f590d55e15b440ddb8f3a7d6070c0e71,
title = "Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications",
abstract = "This chapter discusses the nucleotide excision repair pathway (NER) for therapeutic applications. The NER pathway involves a complex series of reactions and interactions that lead to the effective removal of damage from DNA and is crucial in maintaining genome integrity and stability. The role of NER in removing cisplatin chemotherapy-induced DNA damage and the demonstrated mechanism of resistance in multiple cancers involving increased repair presents the opportunity for intervention. Realization of this potential to sensitize cancers to cisplatin and reverse resistance of those cancers that develop insensitivity to this agent will require the development of specific agents capable of targeting the NER pathway. The possibility exists that the success of platinum therapy in the treatment of testicular cancer can be replicated in lung and ovarian cancers where the lack of response to platinum therapy is a major determinant of the dismal survival statistics associated with those diseases. Such a finding would be a watershed event that could dramatically alter treatments of human cancer.",
author = "John Turchi and Patrick, {Steve M.}",
year = "2012",
doi = "10.1016/B978-0-12-384999-1.10006-X",
language = "English",
isbn = "9780123849991",
pages = "109--117",
booktitle = "DNA Repair in Cancer Therapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications

AU - Turchi, John

AU - Patrick, Steve M.

PY - 2012

Y1 - 2012

N2 - This chapter discusses the nucleotide excision repair pathway (NER) for therapeutic applications. The NER pathway involves a complex series of reactions and interactions that lead to the effective removal of damage from DNA and is crucial in maintaining genome integrity and stability. The role of NER in removing cisplatin chemotherapy-induced DNA damage and the demonstrated mechanism of resistance in multiple cancers involving increased repair presents the opportunity for intervention. Realization of this potential to sensitize cancers to cisplatin and reverse resistance of those cancers that develop insensitivity to this agent will require the development of specific agents capable of targeting the NER pathway. The possibility exists that the success of platinum therapy in the treatment of testicular cancer can be replicated in lung and ovarian cancers where the lack of response to platinum therapy is a major determinant of the dismal survival statistics associated with those diseases. Such a finding would be a watershed event that could dramatically alter treatments of human cancer.

AB - This chapter discusses the nucleotide excision repair pathway (NER) for therapeutic applications. The NER pathway involves a complex series of reactions and interactions that lead to the effective removal of damage from DNA and is crucial in maintaining genome integrity and stability. The role of NER in removing cisplatin chemotherapy-induced DNA damage and the demonstrated mechanism of resistance in multiple cancers involving increased repair presents the opportunity for intervention. Realization of this potential to sensitize cancers to cisplatin and reverse resistance of those cancers that develop insensitivity to this agent will require the development of specific agents capable of targeting the NER pathway. The possibility exists that the success of platinum therapy in the treatment of testicular cancer can be replicated in lung and ovarian cancers where the lack of response to platinum therapy is a major determinant of the dismal survival statistics associated with those diseases. Such a finding would be a watershed event that could dramatically alter treatments of human cancer.

UR - http://www.scopus.com/inward/record.url?scp=84882322443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882322443&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-384999-1.10006-X

DO - 10.1016/B978-0-12-384999-1.10006-X

M3 - Chapter

SN - 9780123849991

SP - 109

EP - 117

BT - DNA Repair in Cancer Therapy

PB - Elsevier Inc.

ER -